4 European Projects Found
Searched on 125080 European Projects
FINISHED
Recognising Adverse Drug Reactions (WEB-RADR)
Start date: Sep 1, 2014, End date: Aug 31, 2017,
WEB-RADR is a consortium of leading experts in pharmacovigilance from regulatory agencies, research, academia and patient support groups. Together with EFPIA partners our aims will be to set policy & guidance and deliver robust information technology tools to address the potential for the reporting of adverse drug reactions (ADRs) through mobile applications and the recognition of drug safety sign ...
Read Project
20
Partners Participants
FINISHED
The potential of human kidney stem/progenitor cells for use in drug discovery and regenerative therapy programmes (NEPHROTOOLS)
Start date: Dec 1, 2011, End date: Nov 30, 2015,
Renal disease is a global public health problem, with the incidence of end stage renal disease (ESRD) rising annually. Current treatment options for ESRD are dialysis or renal transplantation, which have significant drawbacks in terms of increased morbidity and mortality, besides placing an increasing economic burden on society. The development of interventions aimed at preventing ESRD, including ...
Read Project
11
Partners Participants
FINISHED
Buffet Control of Transonic Wings (BUCOLIC)
Start date: Oct 1, 2013, End date: Jun 30, 2015,
"The aim of this work programme is to develop a capability to understand and predict transonic buffet on wings fitted with buffet control devices.Wind tunnel tests will be performed on a half model with buffet control devices fitted to measure dynamic flow characteristics during buffet onset.Unsteady RANS and DES CFD calculations will be carried out, validated against the wind tunnel data. The CF ...
Read Project
2
Partners Participants
FINISHED
Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)
Start date: Jan 1, 2011, End date: Dec 31, 2014,
Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Read Project
